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Abstract
Background: Though vascular factors may be important in the aetiology of late-life depression, it is not clear
whether they have a major effect on the risk of depression after a stroke. We investigated the relationship between
physiological, biochemical, neuro-imaging and socio-economic factors and late-phase post-stroke depression in a
cross-sectional case-control study.
Methods: People living at home at least 9 months after a stroke were interviewed using a structured proforma.
Depression was diagnosed according to DSM-IV criteria, together with a Montgomery Asberg (MADRS) score >17.
Stroke survivors of similar age and functional status but without symptoms of, or recent treatment for, depression
and with MADRS score <7, were recruited as controls.
Results: Stroke survivors with depression were more likely than controls to have been smokers, to have had
hypertension or peripheral arterial disease, and to have had more than one stroke or multiple discrete brainscan
lesions. In univariate analysis they had significantly higher blood pressure, lower Mini-Mental State (MMSE) scores,
higher serum homocysteine and lower folate levels, as well as more extensive white matter and basal ganglia
changes on brainscan. In logistic regression, previous hypertension (OR 3.4), peripheral vascular disease (OR 4.7),
number of strokes (OR 2), MMSE score (OR 0.76) and basal ganglia changes (OR 2.2), were independently
associated with depression.
Conclusion: These results suggest that patients with hypertension, hyperhomocysteinaemia and other factors
associated with cerebral small vessel disease, may be more susceptible to post-stroke depression. Future
intervention trials should focus on such high risk groups.
Background
Although depression is known to be common after a
stroke, consistent risk factors are hard to identify from
the literature and longitudinal studies suggest that cor-
relates may change with time [1]. Little attention has
been paid to biological factors, in contrast with studies
of depression in the general elderly population, where
high blood pressure [2], diabetes [3], coronary artery
disease [4] and other vascular factors [5] have been
found to be important.
The longstanding controversy over the relationship
between the location of the stroke lesion, and the risk of
subsequent depression [6] has perhaps diverted atten-
tion away from other important neuro-imaging findings,
such as the presence of ‘silent’ infarcts, diffuse white
matter changes, cortical and central atrophy, some of
which are associated with late-life depression. The
Mood After Stroke study set out to examine the role of
vascular and other risk factors and ‘chronic’ neuro-
imaging changes (rather than focusing on the location
of the acute stroke lesion) in well defined, clinically
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stroke, using a case-control design with group frequency
matching.
Methods
Patients
Patients living in the community, over 9 months after a
stroke (WHO clinical definition, confirmed by a stroke
physician), without severe cognitive or communication
impairment, were initially screened by post using the
12-item version of the General Health Questionnaire
(GHQ12) [7]. ‘Potential cases of depression’ and possi-
ble controls were approached. From the postal informa-
tion, they were provisionally matched according to age
group and current functional status using the 20-point
Barthel Index [8] of activities of daily living (ADL),
divided into four strata (< 14, 14-18 and 19-20), aiming
to find two possible controls for each potential case in
each stratum.
Interview: Neuro-psychiatric Assessment and Case-Control
categorisation
Those who consented were interviewed, using a struc-
tured proforma, by an investigator (KC) without prior
knowledge of the postal questionnaire responses. As
well as a standardised neuro-psychiatric examination for
DSM-IV [9] classification and Montgomery Asberg
Depression Rating Scale (MADRS) [10], the GHQ12 [7],
Dartmouth COOP chart [11] and ‘Yale’ depression ques-
tion [12] were administered. Cognitive function was
assessed using the Mini-Mental State Examination
(MMSE) [13].
During the interview, the observations and responses
required for the MADRS [10] were noted, and the Diag-
nostic and Statistical Manual (DSM-IV) criteria [9] for
major depression were applied. The final case-control
categorization was made at the time of interview.
Cases were stroke survivors who satisfied DSM-IV
criteria for major depression and had MADRS scores
>17 [14].
Control subjects were stroke survivors who
1 Did not fulfil DSM-IV criteria for major depression
2D i dnot have any minor depressive symptoms at the
time of the interview
3H a dnot been treated for depression within the
previous 6 months
4 Had MADRS score ≤6.
Other Assessments
The Barthel ADL Index [8] was used to assess subjects’
self-care ability and the 66-point Frenchay Activities
Index (FAI) [15] for instrumental, outdoor and social
activities. Self-reported functional status before the
index stroke was assessed using the modified Rankin
score [16] with specific questions on pre-stroke mobility
and continence. Socio-economic factors noted included
the level of formal education, socio-economic class (based
on self-reported former occupation), council tax band (via
postcode) and whether or not they lived alone.
Subjects were asked whether they had been diagnosed
with diabetes, hypertension, atrial fibrillation, ischaemic
heart disease, cardiac failure or peripheral arterial
disease (PAD). Information was later checked against
hospital case notes.
Two sitting blood pressure readings were taken at dif-
ferent points during the interview using a calibrated,
standard, manual mercury sphygmomanometer (intra-
class correlation coefficient between the two readings:
0.9 for systolic and 0.88 for diastolic pressure). Those
with an irregular pulse had an electrocardiogram (ECG)
performed, unless arrhythmia had previously been docu-
mented. If the pulse was regular, ECGs from the case-
notes were checked.
A blood sample was collected for routine blood count
and biochemical tests, C-reactive protein (CRP), total &
HDL cholesterol, triglyceride, serum folate and homo-
cysteine levels. Samples were identified by unique study
number only and transported on ice where necessary.
Serum folate and homocysteine were only measured in
72 control subjects as 14 samples were lost in the
laboratory.
Brain Imaging
Computed Tomography (CT) brain scans, performed
routinely at the time of the ‘index’ acute stroke, were
assessed for chronic changes using a structured
proforma. The rating scale for white matter changes
(WMC) was based on that devised by the European
Task Force [17]. All scans were performed on the same
GE Medical Pro-speed scanner, with 5 mm cuts for the
posterior fossa and 10 mm for the remaining brain. Sub-
jects’ identities were concealed and replaced by a unique
identification number.
For inter-rater reliability analysis, 40 randomly
selected CT brain scans of study subjects were reported
blind by two radiologists and three stroke physicians,
using the same proforma. For the main analysis, all
available scans were reported separately by two investi-
gators, using the same proforma, and consensus ratings
were then agreed.
Further data collection
Details of the index stroke, including Oxfordshire Com-
munity Stroke Project (OCSP) clinical subtype [18] and
presence or absence of aphasia in the initial stages, were
collected from the hospital case-notes and the Gates-
head Stroke Register. The likely location of the acute
stroke lesion was determined clinically and classified as
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stem/cerebellum.
Statistical analysis
We used a frequency matching procedure to minimize
group differences in age and current functional status
(Barthel ADL Index).
Cases and controls were initially compared on single
variables using one-way analysis of variance. Where
appropriate, logarithmic transforms of continuous vari-
ables were performed and geometric means compared.
Mann-Whitney U test was used for non-interval scale or
non-normalisable data, and chi-squared or Fisher’s exact
tests for comparing proportions.
Those variables showing significant effects in univari-
a t ea n a l y s i sw e r ei n c l u d e di nl o g i s t i cr e g r e s s i o nm o d e l s ,
to minimise confounding and examine their indepen-
dent contributions.
Inter-rater reliability for assessing brainscans was mea-
sured using intraclass correlation coefficients (ICC) for
scalable data and Cohen’s kappa for categorical items.
Statistical analysis was performed with SPSS-11 and
EpiInfo-6.
The Local Research Ethics Committees approved this
study.
Results
Between March 2002 and September 2003, 186 patients
were visited at home and 182 were recruited (Figure 1).
Forty of them were found to fulfill the criteria for major
depression, and 87 satisfied the control subject criteria.
The remaining 55 (29%) met neither set of criteria and
were excluded from the analysis. Figure 1 shows the
study profile.
Among the cases, 23 (58%) had mild, 16 (40%) had
moderate and one had severe major depression accord-
ing to DSM-IV criteria [9]. Twenty-seven (67.5%) of
them had been diagnosed with depression after the
stroke but before the interview (6 by psychiatrist, 17 by
general practitioner and 4 by stroke physician). Twenty-
one (53%) of them were on anti-depressant medication.
The mean MADRS score at the time of the interview
was 22 (range 18-37) for the depressed group, compared
with 1 (range 0-6) for the controls.
Functional and cognitive status
Demographic characteristics and index stroke features
are compared between depressed and control subjects in
Table 1. Despite the frequency matching, those in the
depressed group were on average two years younger and
scored one point less on the 20-point Barthel Index
371 
Approached for the study 
129 refused  
56 excluded 
186 
Initially agreed to take part and visited 
2:-Excluded for low MMSE 
1:- Withdrawn Consent 
1:- Feeling ill  182 
Interviewed 
40 
DSM IV ‘Major 
Depression’ 
55 
Excluded 
87 
‘Controls’ 
29 
Diagnosed / treated for Depression in last 
6 months but no Major Depression now 
26 
‘Minor Depressive Symptoms’ 
Figure 1 Study Profile.
Chatterjee et al. BMC Neurology 2010, 10:125
http://www.biomedcentral.com/1471-2377/10/125
Page 3 of 10than controls. There were no significant differences
between the groups in pre-stroke mobility, continence
or modified Rankin scores.
Although differences in basic ADL ability were small,
depressed subjects were much less likely to participate
in outdoor or social activities (FAI) and were much
more aware of limitations in their social participation.
Nearly 90% answered “yes” to questions such as “does
your health stop you getting around?” and “does your
health limit your work and leisure activities?”, compared
with 44% and 33% of controls (p < 0.0001).
Depressed subjects had significantly more cognitive
impairment, with mean MMSE score over 2 points less
than controls. Amongst the components of MMSE,
cases had significantly lower scores for orientation and
recall. As expected, scores on the Euroqol self-rated
quality-of-life index were significantly lower in the
depressed group.
Characteristics of the index stroke
There were no significant differences between the
groups in the time since the index stroke, distribution of
OCSP subtypes (Table 1) or in the side or location of
the acute stroke lesion. Only 2 (2%) patients had
primary intracerebral haemorrhage and 22 (17%) had
posterior circulation strokes, with no difference between
groups.
Socio-economic factors
No significant associations were found between depres-
sion and any of the socio-economic factors assessed,
including marital status, living alone, educational level,
former occupation, recent negative life events and
expressed financial worries.
Vascular and biochemical factors
Table 2 compares vascular and biochemical factors
between cases and controls (univariate analysis).
Those with depression were more likely to have a his-
tory of hypertension or PAD, or to have suffered a
stroke or TIA before their index event. Systolic, diastolic
and mean arterial pressures were significantly higher in
c a s e st h a nc o n t r o l s ,b u tp a t i e n t si nb o t hg r o u p sw e r e
taking a median of two prescribed anti-hypertensive
drugs. On the other hand there were no significant
differences in the prevalence of ischaemic heart disease
or atrial fibrillation between the groups, or in use of
antiplatelet or anticoagulant drugs. Depressed patients
were more likely to be current or ex-smokers, but self-
reported alcohol consumption did not differ between
the groups.
Levels of total serum cholesterol, triglyceride, HDL
and LDL cholesterol were also similar, and no differ-
ences were detected in serum CRP, electrolytes, urea,
creatinine, uric acid, albumin, bilirubin, alkaline phos-
phatase or alanine aminotransferase between cases and
controls.
The (geometric) mean homocysteine level was signifi-
cantly higher, and folate levels correspondingly lower, in
the depressed group although differences were modest
(Table 2). Serum vitamin B12 levels were only measured
in those with serum homocysteine >15 μmol/L, to rule
out subclinical deficiency. No instances were found.
Neuro-imaging findings
Index CT scans were available for analysis for 33 (83%)
of the depressed subjects and 70 (80%) of the controls.
Fifteen patients were not scanned in Gateshead during
the acute phase of their stroke, 5 scans could not be
traced and 4 had MRIs, which were not used for this
analysis. There were no significant differences in demo-
graphic characteristics or vascular risk factors in those
with and without available index scans. Focal lesions
(recent or established) were seen on 64 (62%) of all
scans: 61 ischaemic infarcts, one haemorrhagic infarct
and 2 primary haemorrhages. Other abnormalities were
identified on 14 (14%) scans; mainly atrophy and diffuse
WMCs.
Table 1 Demographics, Functional Status and
Characteristics of Index Stroke
Variable Depressed Controls
nn p *
Age† mean ± SD 40 69 ± 11 87 71 ± 10 0.2
Male 58% 61% 0.9
Functional status
Barthel Index† mean 40 16.5 87 17.6 0.07
(max. 20) median 17 19 0.003
Frenchay Index mean 40 11.1 87 20.0 < .001
(max. 66) median 11 21 < .001
MMSE mean 40 24.4 86 26.8 < .001
(max. 30) median 25 27 < .001
Euroquol mean 40 4.0 87 7.4 < .001
(max. 10) median 4 8 < .001
Clinical features of Index Stroke
Months Since Stroke. median (IQR) 40 25
(18-32)
87 26
(21-33)
0.1
OCSP subtype 37 82
TACS 3 8% 4 5%
PACS 21 57% 46 56%
LACS 8 22% 18 22%
POCS 5 13% 14 17% 0.9
Means: One-way ANOVA, Medians: Mann Whitney, Proportions: Chi squared.
† Variables used for frequency matching.
SD: standard deviation, IQR: inter-quartile range.
TACS: total anterior circulation syndrome, PACS: partial anterior circulation
syndrome,
LACS: lacunar syndrome, POCS: posterior circulation syndrome.
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0.60) among all raters on most items. Agreement was
good for rating central atrophy (ICC = 0.83), but poor
for identifying lacunar infarcts (ICC = 0.33) and
‘WMCs’ within the basal ganglia (ICC = 0.25).
Using the final consensus ratings, the index stroke
scans of depressed subjects were more likely to be
abnormal (91% vs.71%, OR = 4.0), more likely to show
d i s c r e t el e s i o n s ,w h i c hw e r em o r el i k e l yt ob es m a l l
(< 1.5 cm) and/or subcortical. Where acute lesions were
identified, however, there were no significant differences
in their distribution between left and right hemispheres
and brainstem (Table 3).
Overall scores for diffuse white matter changes were
significantly higher in the depressed group than the con-
trols. Frontal and basal ganglia WMC scores were
higher in depressed patients, but within the parieto-occi-
pital region differences did not reach the 5% significance
level. We found no significant increase in lacunar
infarcts in depressed patients and no correlation at all
between depression and the presence or extent of
atrophy (Table 3).
Table 2 Cardiovascular Factors
Variable Depressed (n = 40) Controls
(n = 87)
OR
(95% CI)*
p
Past medical history n % n %
Prior Stroke/TIA 16 40% 16 18% 3.0
(1.2 - 7.4)
0.015
Hypertension 30 75% 47 54% 2.6
(1.0 - 6.4)
0.03
Diabetes 5 13% 14 16% 0.7 0.8
Atrial Fibrillation 8 20% 14 16% 1.3 0.6
Myocardial Infarction 11 28% 23 26% 1.1 1.0
Angina 13 33% 21 24% 1.5 0.4
Peripheral Arterial Disease 9 23% 5 6% 4.8
(1.3 - 18)
0.01
Smoker/Ex-smoker 33 82% 55 63% 2.7
(1.0 - 7.7)
0.038
n Mean ± SD n Mean ± SD
Alcohol (units/week) 40 10.2 ± 4.8 87 8.5 ± 4.5 0.6
Blood Pressure (mmHg)
Systolic 40 156 ± 22 87 147 ± 19 0.025
Diastolic 40 85 ± 12 87 80 ± 12 0.029
Mean Arterial Pressure 40 109 ± 14 87 102 ± 13 0.014
Pulse Pressure 40 71 ± 17 87 67 ± 16 0.22
Biochemistry
Uric Acid 40 0.39 ± 0.14 87 0.4 ± 0.2 0.8
Total Cholesterol mmol/l 40 5.2 ± 1.1 87 5.1 ± 1.1 0.5
LDL-C 40 2.8 ± 1 87 2.8 ± 0.8 0.7
HDL-C 40 1.4 ± 0.4 87 1.3 ± 0.3 0.15
Geometric Mean (95% CI) Geometric Mean
(95% CI)
CRP† 37 5
(3.8-6.6)
76 4
(3.5-4.8)
0.2
Triglyceride† 37 1.9
(1.6-2.3)
82 2.0
(1.8-2.3)
0.8
Platelet Count† 37 267
(240-298)
77 246
(233-259)
0.12
Serum Homocysteine† 37 16.5
(14.5-18.8)
72 14.2
(13.1-15.4)
0.046
Serum Folic Acid† 37 4.7
(3.9-5.6)
73 5.9
(5.2-6.6)
0.03
OR: Odds ratio for depressed vs.control; SD: Standard Deviation;
LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol.
*95% CI: 95% Confidence Interval. Only shown where p < 0.1.
†Logarithmic transform used (geometric means tested for significance).
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Table 4A and 4B show multivariate logistic regression
analysis with presence/absence of depression as depen-
dent variable.
Age and Barthel score were included in all models,
together with those variables significantly associated
with depression in univariate analysis: the total number
of clinical stroke events, history of hypertension, PAD
and smoking, blood pressure readings and MMSE score.
Measures such as FAI and Euroqol were not included,
as low scores were more likely to have been conse-
quences than causes of depression.
As expected, residual effects of the matching variables
were small and statistically insignificant. Table 4A
shows that after multivariate adjustment, the effects of
current or former smoking were no longer significant,
whereas the other variables remained significant. Smok-
ing was therefore eliminated from the model. In the
initial model, ‘history of hypertension’ was associated
with an adjusted OR of 3.4 (95%CI: 1.2-9.5), but once
Table 3 Univariate analysis of CT abnormalities between depressed and controls
Variable Depressed
(n = 33)
Controls
(n = 70)
OR
(95% C.I)
n % n % or p-value
Definite CT Abnormality present
Yes 30 91% 50 71% 4
No 3 9% 20 29% (1 - 18)
Discrete Lesion seen
(acute or chronic)
Yes 26 79% 38 54% 3.1
No 7 21% 32 46% (1.1- 9.2)
Size of the Largest Lesion
(acute or chronic)
< 1.5 cms 12 46% 8 21% 3.2
≥ 1.5 cms 14 54% 30 79% (1.0 - 11.2)
Side of the Lesion
(acute or chronic)
No Lesion 7 21% 32 46%
Right 14 42% 18 26% P = 0.08
Left 9 27% 12 17%
Both Sides 3 9% 8 11%
Location of the Largest Lesion (acute or chronic):
Subcortical (including brainstem) 16 49% 20 29%
Cortical 10 30% 18 26% p = 0.04
No Lesion 7 21% 32 46%
Cortical Atrophy:
Mild/Moderate 15 46% 30 43% 1.1
None 18 54% 40 57% P = 0.8
Central Atrophy:
Mild/Moderate 13 39% 26 37% 1.1
None 20 61% 44 63% P = 0.8
Lacunar Infarcts present
Yes 15 46% 20 29% 2.1
No 18 54% 50 71% P = 0.1
White Matter Changes n Geometric Mean n Geometric Mean p-value
Overall WMC score* 33 0.55 70 0.28 0.013
Basal Ganglia* 0.28 0.16 0.019
Frontal* 0.57 0.30 0.043
Parieto-occipital * 0.36 0.24 0.2
OR: Odds ratio for depressed vs.control;
95% CI: 95% confidence interval. Only shown where p < 0.1.
* Logarithmic transform used (geometric means tested for significance).
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added, the effect of ‘history of hypertension’ became
insignificant and it was therefore dropped from the
‘final basic model’. Serum folate and homocysteine levels
were not included in the basic multivariate model
because the loss of blood samples meant that data from
14 controls would have been entirely lost from the
analysis.
Thus the most important independent predictors of
depression in the basic model were the number of
stroke/TIA events (odds doubled for each event), history
of PAD (odds increased 5-fold if present), mean arterial
pressure and MMSE score at the time of interview.
Other variables were then added into the model indi-
vidually to test their independent effects (Table 4A). Of
the ‘conventional’ vascular risk factors, only diabetes
retained borderline significance, being associated with
an 80% reduction in the odds of depression. After
adjustment, the effects of serum folate and homocys-
teine (log-transformed and only available in 112
patients) were no longer significant. Since the strong
association between peripheral arterial disease and
depression was an unexpected finding, the data were
reanalysed omitting PAD from the basic model, where-
upon the independent effect of homocysteine became
more prominent.
Table 4B shows the same analysis for the 103 patients
with CT scans available. Overall odds ratio estimates
were very similar, except (byc h a n c e )t h o s ef o rs e r u m
homocysteine, which were double those in Table 4A.
Table 4 Multivariate Analysis of Factors Predicting Depression
4A
(39 cases, 86 controls)
4B: (CT results)
(32 cases, 69 controls)
b Adjusted OR 95% CI p b Adjusted OR 95% CI p
Matched Variables
Age -0.03 0.97 0.93 - 1.02 0.2 -0.02 0.98 0.93 - 1.03 0.5
Total BI 0.03 0.97 0.84 - 1.11 0.5 -0.1 0.91 0.78 - 1.1 0.2
’Basic Model’ Variables
Mean Arterial Pressure 0.05 1.05 1.01 - 1.09 0.016 0.05 1.06 1.01 - 1.1 0.016
Total Number of Strokes 0.67 2.0 1.2 - 3.2 0.033 0.59 1.8 1.1 - 3.0 0.024
PAD 1.7 5.4 1.4 - 20.8 0.014 1.5 4.4 0.99 - 19.5 0.052
Total MMSE -0.3 0.74 0.63 - 0.88 < 0.001 -0.2 0.80 0.67 - 0.96 0.015
Folate/Homocysteine
Serum Folate* -0.45 0.64 0.24 - 1.66 0.4 -1.12 0.33 0.1 - 1.05 0.06
Serum Homocysteine* 1.03 2.8 0.69 - 11.5 0.15 1.73 5.6 1.04 - 30.3 0.04
Serum Homocysteine* omitting PAD from model 1.25 3.5 1.0 - 12.7 0.055 2.01 7.5 1.5 - 36.7 0.013
Other Vascular RFs
Diabetes -1.7 0.18 0.03 - 0.98 0.047 -2.8 0.06 0.01 - 0.66 0.02
AF 0.72 2.06 0.57 - 7.41 0.3 1.0 2.7 0.73 - 10.0 0.14
IHD 0.05 1.05 0.40 - 2.78 0.9 0.2 1.2 0.4 - 3.7 0.7
Smoking History 0.46 1.58 0.73 - 3.46 0.2 0.36 1.4 0.62 - 3.3 0.4
CT Scan Findings
Any abnormality visible 1.05 2.9 1.2 - 6.8 0.017
Discrete lesion visible 1.03 2.8 0.9 - 8.7 0.08
Total No. of lesions 0.39 1.5 0.71 - 3.1 0.3
Lesion location
(subcortical vs. cortical)
1.05 2.9 0.95 - 8.6 0.06
Size of the Largest Lesion 0.25 1.3 0.73 - 2.3 0.4
Lacunar Infarct(s) present 0.28 1.3 0.45 - 3.8 0.6
White Matter Changes
Overall WMC Score* 0.39 1.5 0.97 - 2.2 0.07
Basal Ganglia changes* 0.40 1.5 0.97 - 2.3 0.07
Frontal WMCs* 0.22 1.3 0.89 - 1.8 0.2
Parieto-occipital WMCs* 0.09 1.1 0.77 - 1.6 0.6
OR: Odds ratio for depressed vs. control; CT: computed tomography; BI: Barthel Index,
PAD: peripheral arterial disease, RF: risk factor; AF: atrial fibrillation; IHD: ischaemic heart disease; WMCs: white matter changes (includes diffuse ischaemic
changes in basal ganglia).
* Natural logarithmic transform used.
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index CT abnormality was associated with a nearly
3-fold increase in the odds of depression. The presence
of subcortical lesions and high WMC scores, particularly
in the basal ganglia, were of borderline significance after
adjustment.
There was a strong association between overall WMC
score and serum homocysteine (Spearman’s rho = 0.34,
p = 0.001) and both of these were negatively (and possi-
bly causally) associated with MMSE score (rho = -0.21,
p < 0.05 for both variables). Thus the adjusted odds
ratios for depression were recalculated, omitting MMSE
from the basic model, giving a value of 1.56 (95%CI
1.04-2.34, p = 0.03) for overall WMC score, and 6.4
(95%CI 1.31-31.0, p = 0.02) for serum homocysteine
(both log-transformed). Both these associations were
further strengthened when ‘history of PAD’ was also
omitted from the model.
As in univariate analysis, the extent of cortical or cen-
tral atrophy and the presence/absence of lacunar infarcts
had no significant independent effects.
Discussion
Our results clearly indicate that vascular and other
biological factors are important in the aetiology of
late-phase post-stroke depression. Hypertension and
accumulated damage due to previous strokes, especially
in subcortical areas, appear to be key factors. On the
other hand, some strong risk factors for, or indicators
of, large artery atheroma (serum cholesterol, sympto-
matic coronary disease), or cardioembolism (atrial fibril-
lation), showed little or no effect.
In contrast to other studies, which have relied on
screening tests to identify cases of post stroke depres-
sion, we used a strict case definition, based on DSM-IV
criteria, backed up by a high score on the MADRS
scale, a well-validated, reliable assessment, particularly
suited to measuring depression severity [19].
All ratings were made by the same person and our
control subjects all had low MADRS scores, ensuring
wide separation between the groups. Furthermore, sub-
jects were at least 9 months (average over 2 years) post
stroke, eliminating the effect of short term adjustment
reactions.
On the other hand, much information on risk factors
was retrospective and thus potentially open to recall
bias [20]. Nearly all such information was checked from
other sources, however, so that only self-reported
money worries and negative life events were likely to
have been influenced by subjects’ mood.
We used matching to eliminate, as far as possible,
influences on the occurrence of depression of age,
which is complex and nonlinear, and of post-stroke dis-
ability, which is likely to overwhelm the effects of other
factors [21]. Individual matching proved impractical as
cases and controls could not be accurately identified
b e f o r et h ei n t e r v i e w ,s ow eu s e dg r o u pf r e q u e n c y
matching for these variables. This was successful, but it
m e a n tt h a tw ec o u l dn o ti n v e s tigate the effects of age
and physical disability in the analysis.
Brain scans were done many months before the inter-
view for clinical management rather than for study
purposes, and were not available for all subjects. Thus
unknown structural changes could have taken place dur-
ing the intervening period, which might have had a
bearing on the occurrence of depression.
Finally, simultaneous testing for multiple risk factors
increases the risk of identifying chance associations. We
therefore gave priority to analysing associations, which
formed part of our prior hypothesis of a link between
cerebrovascular risk factors and post-stroke depression.
The strong association between a history of peripheral
arterial disease and depression, both in univariate analy-
sis and after adjustment, was unexpected. None of the
subjects interviewed had obvious ischaemic rest pain or
amputations, and no direct measurements of ankle/bra-
chial pressure index were made. Thus classification
depended on a history of claudication or previous treat-
ment for PAD. Since associations between reported
PAD and risk factors such as diabetes and coronary dis-
ease were weak, this classification may have been unreli-
able and the apparent link between PAD and depression
spurious. When PAD was left out of the logistic model,
the strength of association of factors such as homocys-
teine with depression was increased.
The association of serum folate and homocysteine
with depression, significant in univariate analysis, was
also attenuated by the presence of cognitive impairment,
and we found significant associations between low
MMSE scores, serum homocysteine and chronic white
matter changes on CT scan.
Along with physical disability and stroke severity, cog-
nitive impairment is one of the few factors consistently
associated with depression after stroke [21]. The rela-
tionship is complex, but impaired cognition may at least
partly be a consequence of depression and there is some
evidence that effective treatment or spontaneous resolu-
tion of depression may have lasting effects on cognition
[22,23]. Thus it was appropriate to repeat the logistic
regression analysis, omitting the MMSE score from the
model, which significantly increased the odds ratios for
homocysteine and WMC score.
Thus our data are consistent with a causal link
between raised homocysteine levels, white matter
changes on CT scans, cognitive impairment and the
occurrence of post stroke depression. A possible toxic
effect of homocysteine on endothelial function has been
proposed, and raised levels seem to be associated with
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ing as diffuse leukoaraiosis rather than as discrete lacu-
nar infarcts [24]. Evidence is emerging that these two
subtypes of small vessel disease may differ in their
aetiology [25], with atherosclerotic risk factors such as
raised cholesterol, coronary disease and diabetes being
important in the second type, and only hypertension
consistently related to the first.
Our finding that depressed stroke survivors had signif-
i c a n t l ym o r ed i f f u s ec h a n ges in deep white matter and
basal ganglia, but no more lacunar infarcts than nonde-
pressed controls, suggests that post-stroke depression
may be linked with the diffuse type of small vessel dis-
ease but not the discrete lacunar type. Only subcortical
lesions seemed to predict depression; the extent of corti-
cal damage, cortical or central atrophy having no appar-
ent effect. Diffuse changes around the basal ganglia
showed the strongest association, frontal periventricular
changes were of borderline significance, whereas
changes in parieto-occipital white matter showed no dis-
cernable association with depression. These relationships
are strikingly similar to those found by the LADIS
Group [26], who investigated the links between depres-
sive symptoms and MRI white matter changes in non-
disabled older people.
Our finding that both systolic and diastolic pressures,
but not pulse pressure, were significantly associated with
post-stroke depression and cognitive impairment, again
indicates that potentially causal vascular factors may be
acting distal to large arteries. This is consistent with the
findings of the Rotterdam Study, which found no asso-
ciations between measures of large artery stiffness and
cognitive decline, after adjustment for other cardiovas-
cular factors [27].
Thus our results seem to support the ‘vascular depres-
sion hypothesis’ [28], which proposed that vascular
lesions might lead to depression by disrupting prefrontal
circuits or their modulating pathways. Diffuse ischaemic
damage due to small vessel disease, especially around
the basal ganglia and frontal white matter, would be
expected to have a greater effect than multiple discrete
infarcts, and an association between such changes and
late life depression (in contrast to early onset depres-
sion) has been convincingly demonstrated [29].
H o m o c y s t e i n em i g h ta l s ob ei n v o l v e di nt h i sp r o c e s s ,
either by influencing deep white matter changes [30,31],
or possibly through a direct effect on neurotransmitters
[31]. The relationships between homocysteine, other
vascular risk factors, white matter changes, cognitive
impairment and depression are complex and may vary
according to age and the overall level of risk in the
population studied. They areo n l yl i k e l yt ob ed i s e n -
tangled by longitudinal studies and intervention trials
[32] and early findings have cast doubt on some of the
causal links [33-37]. Our results suggest that the best
prospect for testing the ‘homocysteine/vascular hypoth-
esis of depression’ would be to conduct trials of blood
pressure lowering or neurotransmitter modulation and/
or folate and B-vitamin supplementation in high risk
stroke survivors with diffuse small vessel disease.
Conclusion
Our results suggest that history of multiple strokes,
h y p e r t e n s i o n ,s m o k i n g ,p e r ipheral vascular disease and
visible discrete subcortical lesion or basal ganglia
changes on baseline CT brain scans had independent
association with major post-stroke depression at the
chronic phase. Furthermore, patients with major post-
stroke depression had greater degree of cognitive
impairment, higher serum homocysteine and lower
serum folate levels compared with stroke survivors of
similar age and functional ability. Therefore, some risk
factors for small vessel cerebro-vascular disease may
also be risk factors for clinical depression in the chronic
phase after stroke.
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